guest ::
| Home > Publications database > Role of Molecular Dynamics and Related Methods in Drug Discovery > print |
| Home > Publications database > Role of Molecular Dynamics and Related Methods in Drug Discovery > print |
| 001 | 820516 | ||
| 005 | 20240625095122.0 | ||
| 024 | 7 | _ | |a 10.1021/acs.jmedchem.5b01684 |2 doi |
| 024 | 7 | _ | |a 0022-2623 |2 ISSN |
| 024 | 7 | _ | |a 0095-9065 |2 ISSN |
| 024 | 7 | _ | |a 1520-4804 |2 ISSN |
| 024 | 7 | _ | |a 1943-2992 |2 ISSN |
| 024 | 7 | _ | |a WOS:000375969200002 |2 WOS |
| 024 | 7 | _ | |a altmetric:5049162 |2 altmetric |
| 024 | 7 | _ | |a pmid:26807648 |2 pmid |
| 037 | _ | _ | |a FZJ-2016-05808 |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a De Vivo, Marco |0 P:(DE-Juel1)167585 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Role of Molecular Dynamics and Related Methods in Drug Discovery |
| 260 | _ | _ | |a Washington, DC |c 2016 |b ACS |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1478269481_17699 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Molecular dynamics (MD) and related methods are close to becoming routine computational tools for drug discovery. Their main advantage is in explicitly treating structural flexibility and entropic effects. This allows a more accurate estimate of the thermodynamics and kinetics associated with drug–target recognition and binding, as better algorithms and hardware architectures increase their use. Here, we review the theoretical background of MD and enhanced sampling methods, focusing on free-energy perturbation, metadynamics, steered MD, and other methods most consistently used to study drug–target binding. We discuss unbiased MD simulations that nowadays allow the observation of unsupervised ligand–target binding, assessing how these approaches help optimizing target affinity and drug residence time toward improved drug efficacy. Further issues discussed include allosteric modulation and the role of water molecules in ligand binding and optimization. We conclude by calling for more prospective studies to attest to these methods’ utility in discovering novel drug candidates. |
| 536 | _ | _ | |a 899 - ohne Topic (POF3-899) |0 G:(DE-HGF)POF3-899 |c POF3-899 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Masetti, Matteo |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Bottegoni, Giovanni |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Cavalli, Andrea |0 P:(DE-HGF)0 |b 3 |e Corresponding author |
| 773 | _ | _ | |a 10.1021/acs.jmedchem.5b01684 |g Vol. 59, no. 9, p. 4035 - 4061 |0 PERI:(DE-600)1491411-6 |n 9 |p 4035 - 4061 |t Journal of medicinal chemistry |v 59 |y 2016 |x 1520-4804 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/820516/files/acs.jmedchem.5b01684.pdf |y Restricted |
| 856 | 4 | _ | |x icon |u https://juser.fz-juelich.de/record/820516/files/acs.jmedchem.5b01684.gif?subformat=icon |y Restricted |
| 856 | 4 | _ | |x icon-1440 |u https://juser.fz-juelich.de/record/820516/files/acs.jmedchem.5b01684.jpg?subformat=icon-1440 |y Restricted |
| 856 | 4 | _ | |x icon-180 |u https://juser.fz-juelich.de/record/820516/files/acs.jmedchem.5b01684.jpg?subformat=icon-180 |y Restricted |
| 856 | 4 | _ | |x icon-640 |u https://juser.fz-juelich.de/record/820516/files/acs.jmedchem.5b01684.jpg?subformat=icon-640 |y Restricted |
| 856 | 4 | _ | |x pdfa |u https://juser.fz-juelich.de/record/820516/files/acs.jmedchem.5b01684.pdf?subformat=pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:820516 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)167585 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF3-890 |0 G:(DE-HGF)POF3-899 |2 G:(DE-HGF)POF3-800 |v ohne Topic |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a No Authors Fulltext |0 StatID:(DE-HGF)0550 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J MED CHEM : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J MED CHEM : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)IAS-5-20120330 |k IAS-5 |l Computational Biomedicine |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-9-20140121 |k INM-9 |l Computational Biomedicine |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)IAS-5-20120330 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-9-20140121 |
| 981 | _ | _ | |a I:(DE-Juel1)INM-9-20140121 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|